Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer
2007-001506-25Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- May 2007
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and recombinant human interleukin 21 in epithelial ovarian cancer (EOC), sponsored by Novo Nordisk. Primary endpoints: Safety and toxicity (CTCAE v3.0) and dose-limiting toxicity and Overall response rate. Started May 2007; status: terminated.
02
Drugs
pegylated liposomal doxorubicinrecombinant human interleukin 21
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2007-001506-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001506-25.